Veradermics (MANE) closed at $143.85 on October 29, 2026, unchanged from the previous close, on volume of 493,632 shares (30-day average 843,687).
Data as of October 29, 2026.
MANE rallies after Phase 3 Study '304' shows early Month 2 separation and up to 36.4 hairs/cm gain
Market Chameleon (Mon, 19-Oct 7:41 AM ET)
Market Chameleon (Mon, 19-Oct 3:34 AM ET)
Business Wire (Mon, 19-Oct 7:00 AM ET)
Business Wire (Sun, 18-Oct 6:00 PM ET)
Veradermics to Present at Upcoming September Investor Conferences
Business Wire (Thu, 3-Sep 5:33 PM ET)
Business Wire (Tue, 11-Aug 7:30 AM ET)
Market Chameleon (Fri, 17-Jul 7:50 AM ET)
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.
Veradermics trades on the NYSE stock market under the symbol MANE.
As of October 30, 2026, MANE stock price declined to $141.44 with 8,512 million shares trading.
MANE has a beta of 0.25, meaning it tends to be less sensitive to market movements. MANE has a correlation of 0.00 to the broad based SPY ETF.
MANE has a market cap of $5.91 billion. This is considered a Mid Cap stock.
The top ETF exchange traded funds that MANE belongs to (by Net Assets): VTI, IWM, VXF, JGRO, SCHA.
MANE support price is $136.47 and resistance is $151.24 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MANE shares will trade within this expected range on the day.
